Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Learn more in our full Noom Review
Plant Dev 1938
Avoid use if you have severe kidney disease or are on dialysis unless closely supervised by a nephrologist
Its mechanism involves reducing hepatic glucose production and improving insulin sensitivity, which indirectly affects appetite and fat storage
After the SELECT trial cardiovascular indication for Wegovy (FDA approved March 2024) and the SURMOUNT-OSA approval for Zepbound (December 2024), Aetna added separate coverage pathways for those medical indications, which often bypass the obesity carve-outs
This product is manufactured for researchers studying peptide chemistry, molecular interactions, analytical methodologies, formulation development, and other laboratory applications involving synthetic peptides
US$ 25.41
US$ 26.66
US$ 29.68
